Cargando…
Angiopoietin-2 Serum Levels Improve Noninvasive Fibrosis Staging in Chronic Hepatitis C: A Fibrogenic-Angiogenic Link
AIMS: Accurate liver fibrosis staging is crucial for the management of chronic hepatitis C (CHC). The invasiveness and cost burden of liver biopsy have driven the search for new noninvasive biomarkers of fibrosis. Based on the link between serum angiopoietin-1 and 2 levels and CHC progression, we ai...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3688858/ https://www.ncbi.nlm.nih.gov/pubmed/23823085 http://dx.doi.org/10.1371/journal.pone.0066143 |
_version_ | 1782274181244649472 |
---|---|
author | Hernández-Bartolomé, Ángel López-Rodríguez, Rosario Rodríguez-Muñoz, Yolanda Martín-Vílchez, Samuel Borque, María Jesús García-Buey, Luisa González-Moreno, Leticia Real, Yolanda Moreno-Otero, Ricardo Sanz-Cameno, Paloma |
author_facet | Hernández-Bartolomé, Ángel López-Rodríguez, Rosario Rodríguez-Muñoz, Yolanda Martín-Vílchez, Samuel Borque, María Jesús García-Buey, Luisa González-Moreno, Leticia Real, Yolanda Moreno-Otero, Ricardo Sanz-Cameno, Paloma |
author_sort | Hernández-Bartolomé, Ángel |
collection | PubMed |
description | AIMS: Accurate liver fibrosis staging is crucial for the management of chronic hepatitis C (CHC). The invasiveness and cost burden of liver biopsy have driven the search for new noninvasive biomarkers of fibrosis. Based on the link between serum angiopoietin-1 and 2 levels and CHC progression, we aimed to determine the value of these angiogenic factors as noninvasive biomarkers of liver fibrosis. METHODS: Serum levels of angiopoietin-1 and -2 were measured by ELISA in 108 CHC patients who underwent pretreatment liver biopsy. The correlation between angiopoietins and clinical and demographic variables with liver fibrosis was analyzed by univariate regression. Significant factors were then subjected to multivariate analysis, from which we constructed a novel noninvasive liver fibrosis index (AngioScore), whose performance was validated in an independent series of 71 CHC patients. The accuracy of this model was compared with other documented fibrosis algorithms by De Long test. RESULTS: Angiopoietins correlated significantly with hepatic fibrosis; however, only angiopoietin-2 was retained in the final model, which also included age, platelets, AST, INR, and GGT. The model was validated and behaved considerably better than other fibrosis indices in discriminating all, significant, moderate and severe liver fibrosis (0.886, 0.920, 0.923). Using clinically relevant cutoffs, we classified CHC patients by discarding significant fibrosis and diagnosing moderate and severe fibrosis with greater accuracy, sensitivity, and specificity. CONCLUSIONS: Our novel noninvasive liver fibrosis model, based on serum angiopoietin-2 levels, outperforms other indices and should help substantially in managing CHC and monitoring long-term follow-up prognosis. |
format | Online Article Text |
id | pubmed-3688858 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-36888582013-07-02 Angiopoietin-2 Serum Levels Improve Noninvasive Fibrosis Staging in Chronic Hepatitis C: A Fibrogenic-Angiogenic Link Hernández-Bartolomé, Ángel López-Rodríguez, Rosario Rodríguez-Muñoz, Yolanda Martín-Vílchez, Samuel Borque, María Jesús García-Buey, Luisa González-Moreno, Leticia Real, Yolanda Moreno-Otero, Ricardo Sanz-Cameno, Paloma PLoS One Research Article AIMS: Accurate liver fibrosis staging is crucial for the management of chronic hepatitis C (CHC). The invasiveness and cost burden of liver biopsy have driven the search for new noninvasive biomarkers of fibrosis. Based on the link between serum angiopoietin-1 and 2 levels and CHC progression, we aimed to determine the value of these angiogenic factors as noninvasive biomarkers of liver fibrosis. METHODS: Serum levels of angiopoietin-1 and -2 were measured by ELISA in 108 CHC patients who underwent pretreatment liver biopsy. The correlation between angiopoietins and clinical and demographic variables with liver fibrosis was analyzed by univariate regression. Significant factors were then subjected to multivariate analysis, from which we constructed a novel noninvasive liver fibrosis index (AngioScore), whose performance was validated in an independent series of 71 CHC patients. The accuracy of this model was compared with other documented fibrosis algorithms by De Long test. RESULTS: Angiopoietins correlated significantly with hepatic fibrosis; however, only angiopoietin-2 was retained in the final model, which also included age, platelets, AST, INR, and GGT. The model was validated and behaved considerably better than other fibrosis indices in discriminating all, significant, moderate and severe liver fibrosis (0.886, 0.920, 0.923). Using clinically relevant cutoffs, we classified CHC patients by discarding significant fibrosis and diagnosing moderate and severe fibrosis with greater accuracy, sensitivity, and specificity. CONCLUSIONS: Our novel noninvasive liver fibrosis model, based on serum angiopoietin-2 levels, outperforms other indices and should help substantially in managing CHC and monitoring long-term follow-up prognosis. Public Library of Science 2013-06-18 /pmc/articles/PMC3688858/ /pubmed/23823085 http://dx.doi.org/10.1371/journal.pone.0066143 Text en © 2013 Hernández-Bartolomé et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Hernández-Bartolomé, Ángel López-Rodríguez, Rosario Rodríguez-Muñoz, Yolanda Martín-Vílchez, Samuel Borque, María Jesús García-Buey, Luisa González-Moreno, Leticia Real, Yolanda Moreno-Otero, Ricardo Sanz-Cameno, Paloma Angiopoietin-2 Serum Levels Improve Noninvasive Fibrosis Staging in Chronic Hepatitis C: A Fibrogenic-Angiogenic Link |
title | Angiopoietin-2 Serum Levels Improve Noninvasive Fibrosis Staging in Chronic Hepatitis C: A Fibrogenic-Angiogenic Link |
title_full | Angiopoietin-2 Serum Levels Improve Noninvasive Fibrosis Staging in Chronic Hepatitis C: A Fibrogenic-Angiogenic Link |
title_fullStr | Angiopoietin-2 Serum Levels Improve Noninvasive Fibrosis Staging in Chronic Hepatitis C: A Fibrogenic-Angiogenic Link |
title_full_unstemmed | Angiopoietin-2 Serum Levels Improve Noninvasive Fibrosis Staging in Chronic Hepatitis C: A Fibrogenic-Angiogenic Link |
title_short | Angiopoietin-2 Serum Levels Improve Noninvasive Fibrosis Staging in Chronic Hepatitis C: A Fibrogenic-Angiogenic Link |
title_sort | angiopoietin-2 serum levels improve noninvasive fibrosis staging in chronic hepatitis c: a fibrogenic-angiogenic link |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3688858/ https://www.ncbi.nlm.nih.gov/pubmed/23823085 http://dx.doi.org/10.1371/journal.pone.0066143 |
work_keys_str_mv | AT hernandezbartolomeangel angiopoietin2serumlevelsimprovenoninvasivefibrosisstaginginchronichepatitiscafibrogenicangiogeniclink AT lopezrodriguezrosario angiopoietin2serumlevelsimprovenoninvasivefibrosisstaginginchronichepatitiscafibrogenicangiogeniclink AT rodriguezmunozyolanda angiopoietin2serumlevelsimprovenoninvasivefibrosisstaginginchronichepatitiscafibrogenicangiogeniclink AT martinvilchezsamuel angiopoietin2serumlevelsimprovenoninvasivefibrosisstaginginchronichepatitiscafibrogenicangiogeniclink AT borquemariajesus angiopoietin2serumlevelsimprovenoninvasivefibrosisstaginginchronichepatitiscafibrogenicangiogeniclink AT garciabueyluisa angiopoietin2serumlevelsimprovenoninvasivefibrosisstaginginchronichepatitiscafibrogenicangiogeniclink AT gonzalezmorenoleticia angiopoietin2serumlevelsimprovenoninvasivefibrosisstaginginchronichepatitiscafibrogenicangiogeniclink AT realyolanda angiopoietin2serumlevelsimprovenoninvasivefibrosisstaginginchronichepatitiscafibrogenicangiogeniclink AT morenooteroricardo angiopoietin2serumlevelsimprovenoninvasivefibrosisstaginginchronichepatitiscafibrogenicangiogeniclink AT sanzcamenopaloma angiopoietin2serumlevelsimprovenoninvasivefibrosisstaginginchronichepatitiscafibrogenicangiogeniclink |